Pfizer wins backing for Sutent patent; Private equity kicking tires at Bayer's plastics unit;

@FiercePharma: Top-read in FP Wednesday: $GSK dealmaking spawns management shake-up, putting Slaoui and Hussain in top slots. Article | Follow @FiercePharma

@CarlyHFierce: Novartis drafts TV celeb Nick Cannon to talk up importance of flu vaccines. FierceVaccines item | More from FiercePharmaMarketing | Follow @CarlyHFierce

> A U.S. district court backed Pfizer's ($PFE) patent on the kidney cancer drug Sutent, which the generics maker Mylan ($MYL) had challenged. Report

> Private equity firms are eyeing Bayer's plastics business, which it plans to sell off to focus on its healthcare and crop science units. Report

> A U.S. appeals court upheld Actavis' ($ACT) patents on the hormonal contraceptive pill Lo Loestrin Fe. Release

> Purdue Pharma launched a new program to train pharmacists in counseling patients who use opioid pain relievers. Report

Medical Device News

@FierceMedDev: Mobile blood glucose monitor startup Telcare gets $33M round. Article | Follow @FierceMedDev

@VarunSaxena2: Sanofi leads $11M Series A round for needle-free delivery company. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: U.S. Department of Homeland Security investigating cybersecurity concerns for devices from $MDT, $STJ and $HSP. More | Follow @EmilyWFierce

@MichaelGFierce: Encapsulated Alzheimer's, Parkinson's-treating growth factors implanted directly in the brain. FierceDrugDelivery article | Follow @MichaelGFierce

> Private insurers squeezing device companies in bid to limit costs. More

> Enigma Diagnostics eyes China market with $50M and a JV. Article

Biotech News

@FierceBiotech: J&J heads to Texas with its R&D farm system, scouting for biotech startups. News | Follow @FierceBiotech

@JohnCFierce: Celgene adds $1B-plus immuno-oncology deal, buyout option for Sutro, a Fierce 15 company. News | Follow @JohnCFierce

@DamianFierce: Inbox: "FDA Encourages Juice Safety This Fall"; juice safely, everyone. | Follow @DamianFierce

@EmilyMFierce: Sigh. US midterm elections offer little hope for science. More from Nature | Follow @EmilyMFierce

> Women's health biotech Forendo raises $15M from some pharma giants. Item

> Lilly bets another $375M on Zymeworks' two-pronged cancer tech. Story

> Pfizer, Novartis chip in on $17M round for an Atlas upstart focused on pain. Article

Vaccines News

> Could oral vaccines shake up the flu shot market? Vaxart's Ph I says maybe. More

> GSK taps Slaoui to chair flat-selling vaccines unit with an eye to the future. Story

> Novartis drafts TV celeb Nick Cannon to talk up importance of flu vaccines. Item

> Ebola roundup: J&J invests $200M in R&D, Glaxo says vaccine will come too late. More

> FDA accepts app for Merck, Sanofi 6-in-1 combo vaccine. Article

Pharma Manufacturing News

> Roche, too, has big plans for improved HQ facilities. Item

> Industry faces new effort to make it pay for drug disposal. More

> Repackager mistakenly puts some ibuprofen bottles into naproxen boxes. Report

> GSK manufacturing will take hit in cost-cutting move. Story

> Argos starts work on $57M plant in North Carolina. Article

And Finally... The City of Baltimore won't help employees and retirees cover the reimbursement gap for Medicare drugs beginning in 2020, saying Obamacare plans will pick up those costs. Report

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.